Fair Value Accounting - Additional Information (Detail) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended
	Sep. 30, 2020	Jan. 31, 2016	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Jun. 30, 2018
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change in contingent consideration					$ 957,000	$ 3,188,000
Minimum
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Percentage of probabilities of contingent consideration successful achievement milestone discount rates range					12.20%
Maximum
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Percentage of probabilities of contingent consideration successful achievement milestone discount rates range					13.50%
Integrated Diagnostics, Inc
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of contingent consideration recognized on acquisition date							$ 19,600,000
Change in contingent consideration resulting from the accretion of the liability offset			$ 1,000,000.0		$ 2,900,000
Change in contingent consideration due to the impact of the deceleration of expected revenue and decreases in expected costs			0		1,900,000
Change in contingent consideration						3,200,000
Change in contingent consideration resulting from the impact of the acceleration of expected revenue and decreases in expected costs						700,000
Change in contingent consideration resulting from accretion of liability				$ 900,000		$ 2,500,000
Series F Preferred Stock
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Calculated number of contingent value rights received by investors, if financing raised exceed the amount		$ 20,202,323
Contingent value rights shares		3,999
Contingent value rights	$ 0	$ 500,000	0		0
Net proceeds percentage of cash payment to the CVR holders		15.00%
Development and regulatory costs payable	$ 300,000		$ 300,000		$ 300,000
Drug Ficlatuzumab | Series F Preferred Stock
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent value right, percentage multiplier		0.00375%
AVEO Oncology | Series F Preferred Stock
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Percentage of development and regulatory costs exercised using opt-out right	50.00%